person · Reporting owner

Schwartz Jeffrey Lawrence

Disclosed activity across 10 companies

Tapewire entity: 75682
SEC CIK: 0001702957

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Aptinyx Inc.APTX · Entity 120922	10% owner	October 26, 2020	October 27, 2020
Arcutis Biotherapeutics, Inc.ARQT · Entity 4236	10% owner	February 04, 2020	February 06, 2020
BCLS Acquisition Corp.BLSA · Entity 145747	Director · Chief Executive Officer · 10% owner	October 26, 2020	October 26, 2020
Dicerna Pharmaceuticals IncDRNA · Entity 131951	10% owner	November 19, 2019	November 21, 2019
KESTRA MEDICAL TECHNOLOGIES, LTD.KMTS · Entity 4686	Director · 10% owner	September 08, 2026	September 11, 2026
RAPID MICRO BIOSYSTEMS, INC.RPID · Entity 6966	Director · 10% owner	May 23, 2024	May 28, 2024
SpringWorks Therapeutics, Inc.SWTX · Entity 15910	Director	May 24, 2023	May 25, 2023

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Aptinyx Inc.

Report date October 26, 2020 · Filed October 27, 2020

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, Koppel Adam

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	8,891,758	Reported balance After 2020-10-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-10-26 · Purchase · Acquired 3,333,333 · Balance 8,891,758 F1: On October 26, 2020, Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Fund, LP ("BCIPLS and, together with BCLS, the "Bain Capital Life Sciences Entities") purchased an aggregate of 3,333,333 shares of Common Stock in an underwritten public offering at a price per share of $3.00. BCLS purchased 3,023,816 of such shares and BCIPLS purchased 309,517 of such shares. Following such purchases, BCLS holds 8,066,113 shares of Common Stock and BCIPLS holds 825,645 shares of Common Stock. F2: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F3: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. F4: Adam Koppel is a director of the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: On October 26, 2020, Bain Capital Life Sciences Fund, L.P. ("BCLS") and BCIP Life Sciences Fund, LP ("BCIPLS and, together with BCLS, the "Bain Capital Life Sciences Entities") purchased an aggregate of 3,333,333 shares of Common Stock in an underwritten public offering at a price per share of $3.00. BCLS purchased 3,023,816 of such shares and BCIPLS purchased 309,517 of such shares. Following such purchases, BCLS holds 8,066,113 shares of Common Stock and BCIPLS holds 825,645 shares of Common Stock.

F2: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F3: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the shares of Common Stock held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F4: Adam Koppel is a director of the Issuer.

Arcutis Biotherapeutics, Inc.

Report date February 04, 2020 · Filed February 06, 2020

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, Koppel Adam

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,825,602	Reported balance After 2020-02-04 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-02-04 · Conversion · Acquired 2,825,602 · Balance 2,825,602 F1: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date. F2: Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"). F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,685,175	Reported balance After 2020-02-04 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-02-04 · Conversion · Acquired 859,573 · Balance 3,685,175 F1: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date. F3: Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS. F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,979,292	Reported balance After 2020-02-04 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-02-04 · Purchase · Acquired 294,117 · Balance 3,979,292 F4: Represents 266,807 and 27,310 shares of Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering. F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-02-04 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-02-04 · Conversion · Disposed 2,825,602 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date. F2: Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"). F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-02-04 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-02-04 · Conversion · Disposed 859,573 · Balance 0 F1: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date. F3: Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS. F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series B Preferred Stock ("Series B Stock") and Series C Preferred Stock ("Series C Stock") automatically converted into 1 share of the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. The Series B Stock and the Series C Stock each had no expiration date.

F2: Represents 2,563,231 shares of Series B Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 262,371 shares of Series B Stock held of record by BCIP Life Sciences Associates, LP. ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").

F3: Represents 779,758 shares of Series C Stock held of record by BCLS and 79,815 shares of Series C Stock held of record by BCIPLS.

F4: Represents 266,807 and 27,310 shares of Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering.

F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coninvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dipositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

BCLS Acquisition Corp.

Report date October 26, 2020 · Filed October 26, 2020

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A ordinary sharesSEC Table I · non-derivative	IndirectSee Footnote	487,500	Reported balance After 2020-10-26 transaction · row 1 Account identity is unresolved; indirect or unspecified ownership is not merged. 1 source row Row 1 · 2020-10-26 · Grant · Acquired 487,500 · Balance 487,500 F1: The reported Class A ordinary shares were purchased from the Issuer in a private placement by BCLS Acquisition Holdings, LP (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-249284). F2: The shares are held by the Sponsor. The Sponsor is controlled by its general partner, BCLS Acquisition Holdings (GP), LLC (the "General Partner"), which is governed by a board of managers consisting of three managers. Each manager has one vote, and the approval of a majority of the managers is required to approve an action on behalf of the Sponsor. Jeffrey Schwartz serves on the board of managers of the General Partner. As a result, Mr. Schwartz may be deemed to share beneficial ownership of the shares held by the Sponsor. Mr. Schwartz disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The reported Class A ordinary shares were purchased from the Issuer in a private placement by BCLS Acquisition Holdings, LP (the "Sponsor") for $10.00 per share, as described in the Issuer's registration statement on Form S-1 (File No. 333-249284).

F2: The shares are held by the Sponsor. The Sponsor is controlled by its general partner, BCLS Acquisition Holdings (GP), LLC (the "General Partner"), which is governed by a board of managers consisting of three managers. Each manager has one vote, and the approval of a majority of the managers is required to approve an action on behalf of the Sponsor. Jeffrey Schwartz serves on the board of managers of the General Partner. As a result, Mr. Schwartz may be deemed to share beneficial ownership of the shares held by the Sponsor. Mr. Schwartz disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.

Dicerna Pharmaceuticals Inc

Report date November 19, 2019 · Filed November 21, 2019

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, Koppel Adam

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	5,580,237	Reported balance After 2019-11-19 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-11-19 · Sale · Disposed 1,750,000 · Balance 5,580,237 F1: On November 19, 2019 Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Capital Life Sciences Entities") sold 1,582,973 and 167,027 shares of common stock, respectively, pursuant to Rule 144 under the Securities Act of 1933, as amended. F2: Dr. Koppel is a director of the Issuer. F3: Bain Capital Life Sciences Partners, LP ("BC LS P") is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F4: Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC. As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On November 19, 2019 Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Capital Life Sciences Entities") sold 1,582,973 and 167,027 shares of common stock, respectively, pursuant to Rule 144 under the Securities Act of 1933, as amended.

F2: Dr. Koppel is a director of the Issuer.

F3: Bain Capital Life Sciences Partners, LP ("BC LS P") is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. BC LS P disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

F4: Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BC LS P and governs the investment strategy and decision-making process with respect to investments held by BCIP LS, whose general partner is Boylston Coinvestors, LLC. As a result of the relationships described herein, each of BCI LS, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

KESTRA MEDICAL TECHNOLOGIES, LTD.

Report date September 08, 2026 · Filed September 11, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	Direct	14,236	Ending reported balance After 2026-09-09 transaction · row 2 2 source rows · reconciled sequence Row 1 · 2026-09-08 · Sale · Disposed 3,890 · Balance 7,019 F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units. F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4240. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range. Row 2 · 2026-09-09 · Grant · Acquired 7,217 · Balance 14,236 F3: The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 9, 2027, subject to the Reporting Person's continued service through such date.
Common SharesSEC Table I · non-derivative	IndirectSee footnote	25,172,338	Reported balance Holding disclosure · report date 2026-09-08 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 25,172,338 F4: Represents 25,172,338 common shares of the Issuer held directly by Bain Charger Holdings, L.P. ("Bain Charger"). Mr. Schwartz is a Partner of Bain Capital Investors, LLC, which is the general partner of Bain Charger. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by Bain Charger. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The sale reported in this Form 4 represents a nondiscretionary sale of shares required to be sold by the reporting person pursuant to sell to cover transactions to satisfy tax withholding obligations in connection with the vesting and settlement of restricted stock units.

F2: The price in Column 4 is a weighted average price. The prices at which the reported securities were sold ranged from $24.9100 to $25.4240. Upon request, the reporting person will provide to the Issuer, any security holder of the Issuer, or the SEC staff, information regarding the number of shares at each price within the range.

F3: The reported securities represent restricted stock units ("RSUs") which each entitle the Reporting Person to receive one common share of the Issuer. The RSUs will vest on September 9, 2027, subject to the Reporting Person's continued service through such date.

F4: Represents 25,172,338 common shares of the Issuer held directly by Bain Charger Holdings, L.P. ("Bain Charger"). Mr. Schwartz is a Partner of Bain Capital Investors, LLC, which is the general partner of Bain Charger. As a result, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by Bain Charger. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

RAPID MICRO BIOSYSTEMS, INC.

Report date May 23, 2024 · Filed May 28, 2024

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	14,300	Reported balance After 2024-05-23 transaction · row 1 1 source row Row 1 · 2024-05-23 · Grant · Acquired 14,300 · Balance 14,300 F1: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2034-05-22	Direct	28,650	Reported balance After 2024-05-23 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-05-23 · Grant · Acquired 28,650 · Balance 28,650 F2: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnotes	8,434,560	Reported balance Holding disclosure · report date 2024-05-23 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 8,434,560 F3: Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS Fund I") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS Fund I, the "Bain Capital Life Sciences Entities"). F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS Fund I and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Mr. Schwartz is a Partner of BCLSI. By virtue of the relationships described in this footnote, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Grant of restricted stock units ("RSUs") that vests in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.

F2: The option shall vest and become exercisable in full on the earlier of (i) the first anniversary of the grant date or (ii) the day immediately prior to the date of the next annual meeting of the stockholders of the Company, provided that the reporting person remains in continuous service on such vesting date.

F3: Represents shares of Class A Common Stock held directly by Bain Capital Life Sciences Fund, L.P. ("BCLS Fund I") and BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS Fund I, the "Bain Capital Life Sciences Entities").

F4: Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLS Fund I and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Mr. Schwartz is a Partner of BCLSI. By virtue of the relationships described in this footnote, Mr. Schwartz may be deemed to share voting and dispositive power with respect to the securities held by the Bain Capital Life Sciences Entities. Mr. Schwartz disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

SpringWorks Therapeutics, Inc.

Report date May 24, 2023 · Filed May 25, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	10,572	Reported balance After 2023-05-24 transaction · row 1 1 source row Row 1 · 2023-05-24 · Grant · Acquired 4,648 · Balance 10,572 F1: This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.27 · Expires 2033-05-24	Direct	13,774	Reported balance After 2023-05-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2023-05-24 · Grant · Acquired 13,774 · Balance 13,774 F2: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. F3: The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,081,307	Reported balance Holding disclosure · report date 2023-05-24 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 3,081,307 F4: Represents shares of common stock held directly by BC SW, LP. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of BC SW, LP. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC SW, LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: This transaction represents a grant of restricted stock units ("RSUs") pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders. The RSUs shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.

F2: This transaction represents a grant of options pursuant to the terms of the Issuer's Amended and Restated Non-Employee Director Compensation Policy which provides for annual equity grants to the Issuer's non-employee directors on the date of the Issuer's annual meeting of stockholders.

F3: The options shall vest in full on the earlier of (1) May 24, 2024 and (2) the next annual meeting of stockholders, subject to continued service to the Issuer by the Reporting Person.

F4: Represents shares of common stock held directly by BC SW, LP. Bain Capital Life Sciences Investors, LLC ("BCLSI") is the general partner of BC SW, LP. The Reporting Person is a Partner of BCLSI. As a result, the Reporting Person may be deemed to share voting and dispositive power with respect to the shares of common stock held by BC SW, LP. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Past disclosures · reporting ended (3)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Annexon, Inc.

Report date July 28, 2020 · Filed July 28, 2020

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, Koppel Adam, Bain Capital Life Sciences Partners, LP

Section 16 reporting ended · disclosed 2020-07-28. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,522,385	Reported balance After 2020-07-28 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2020-07-28 · Conversion · Acquired 2,522,385 · Balance 2,522,385 F1: Each share of Series C Preferred Stock ("Series C Stock") and Series D Preferred Stock ("Series D Stock") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. F2: Represents 20,158,775 shares of Series C Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 2,063,446 shares of Series C Stock held of record by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"). F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,841,628	Reported balance After 2020-07-28 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-07-28 · Conversion · Acquired 319,243 · Balance 2,841,628 F1: Each share of Series C Preferred Stock ("Series C Stock") and Series D Preferred Stock ("Series D Stock") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. F3: Represents 2,551,384 shares of Series D Stock held of record by BCLS and 261,159 shares of Series D Stock held of record by BCIPLS. F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	3,241,628	Reported balance After 2020-07-28 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2020-07-28 · Purchase · Acquired 400,000 · Balance 3,241,628 F4: Represents 362,858 and 37,142 shares of the Issuer's Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering. F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-07-28 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-28 · Conversion · Disposed 22,222,221 · Balance 0 F1: Each share of Series C Preferred Stock ("Series C Stock") and Series D Preferred Stock ("Series D Stock") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. F2: Represents 20,158,775 shares of Series C Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 2,063,446 shares of Series C Stock held of record by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities"). F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnotes	0	Reported balance After 2020-07-28 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-07-28 · Conversion · Disposed 2,812,543 · Balance 0 F1: Each share of Series C Preferred Stock ("Series C Stock") and Series D Preferred Stock ("Series D Stock") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering. F3: Represents 2,551,384 shares of Series D Stock held of record by BCLS and 261,159 shares of Series D Stock held of record by BCIPLS. F5: Bain Capital Life Sciences Partners, LP ("BCLSP") is the general partner of BCLS. As a result, BCLSP may be deemed to share voting and dispositive power with respect to the securities held by BCLS. BCLSP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein. F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of Series C Preferred Stock ("Series C Stock") and Series D Preferred Stock ("Series D Stock") automatically converted on a 1-for-8.81 basis into the Issuer's Common Stock immediately prior to the closing of the Issuer's initial public offering.

F2: Represents 20,158,775 shares of Series C Stock held of record by Bain Capital Life Sciences Fund, L.P. ("BCLS") and 2,063,446 shares of Series C Stock held of record by BCIP Life Sciences Associates, LP ("BCIPLS" and, together with BCLS, the "Bain Capital Life Sciences Entities").

F3: Represents 2,551,384 shares of Series D Stock held of record by BCLS and 261,159 shares of Series D Stock held of record by BCIPLS.

F4: Represents 362,858 and 37,142 shares of the Issuer's Common Stock purchased by BCLS and BCIPLS, respectively, in the Issuer's initial public offering.

F6: Bain Capital Life Sciences Investors, LLC ("BCLSI"), whose managers are Jeffrey Schwartz and Adam Koppel, is the general partner of BCLSP and governs the investment strategy and decision-making process with respect to investments held by BCIPLS, whose general partner is Boylston Coinvestors, LLC. As a result, each of BCLSI, Mr. Schwartz and Dr. Koppel may be deemed to share voting and dispositive power over the shares held by the Bain Capital Life Sciences Entities. BCLSI, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

MARINUS PHARMACEUTICALS, INC.

Report date December 15, 2017 · Filed December 20, 2017

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, Koppel Adam

Section 16 reporting ended · disclosed 2017-12-20. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnotes	3,977,453	Last balance in matching sequence After 2017-12-19 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 5 source rows Row 1 · 2017-12-15 · Sale · Disposed 719,665 · Balance 4,530,335 F1: On December 15, 2017, Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Life Sciences Entities") sold 652,840 and 66,825 shares of common stock, respectively, at a weighted average price of $8.0179. The shares were sold in multiple transactions at prices ranging from $7.89 to $8.495. Following such sales, BC LS and BCIP LS held 4,109,671 and 420,664 shares of common stock, respectively. F6: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 2 · 2017-12-15 · Sale · Disposed 102,882 · Balance 4,427,453 F2: On December 15, 2017, BC LS and BCIP LS sold 93,329 and 9,553 shares of common stock, respectively, at a weighted average price of $8.636. The shares were sold in multiple transactions at prices ranging from $8.50 to $9.045. Following such sales, BC LS and BCIP LS held 4,016,342 and 411,111 shares of common stock, respectively. F6: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 3 · 2017-12-18 · Sale · Disposed 300,000 · Balance 4,127,453 F3: On December 18, 2017, BC LS and BCIP LS sold 272,143 and 27,857 shares of common stock, respectively, at a weighted average price of $7.5048. The shares were sold in multiple transactions at prices ranging from $7.05 to $7.905. Following such sales, BC LS and BCIP LS held 3,744,199 and 383,254 shares of common stock, respectively. F6: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 4 · 2017-12-19 · Sale · Disposed 94,771 · Balance 4,032,682 F4: On December 19, 2017, BC LS and BCIP LS sold 85,971 and 8,800 shares of common stock, respectively, at a weighted average price of $7.6209. The shares were sold in multiple transactions at prices ranging from $7.50 to $8.02. Following such sales, BC LS and BCIP LS held 3,658,228 and 374,454 shares of common stock, respectively. F6: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Row 5 · 2017-12-19 · Sale · Disposed 55,229 · Balance 3,977,453 F5: On December 19, 2017, BC LS and BCIP LS sold 50,101 and 5,128 shares of common stock, respectively, at a weighted average price of $7.1055. The shares were sold in multiple transactions at prices ranging from $6.86 to $7.498. Following such sales, BC LS and BCIP LS held 3,608,127 and 369,326 shares of common stock, respectively. F6: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: On December 15, 2017, Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Life Sciences Entities") sold 652,840 and 66,825 shares of common stock, respectively, at a weighted average price of $8.0179. The shares were sold in multiple transactions at prices ranging from $7.89 to $8.495. Following such sales, BC LS and BCIP LS held 4,109,671 and 420,664 shares of common stock, respectively.

F2: On December 15, 2017, BC LS and BCIP LS sold 93,329 and 9,553 shares of common stock, respectively, at a weighted average price of $8.636. The shares were sold in multiple transactions at prices ranging from $8.50 to $9.045. Following such sales, BC LS and BCIP LS held 4,016,342 and 411,111 shares of common stock, respectively.

F3: On December 18, 2017, BC LS and BCIP LS sold 272,143 and 27,857 shares of common stock, respectively, at a weighted average price of $7.5048. The shares were sold in multiple transactions at prices ranging from $7.05 to $7.905. Following such sales, BC LS and BCIP LS held 3,744,199 and 383,254 shares of common stock, respectively.

F4: On December 19, 2017, BC LS and BCIP LS sold 85,971 and 8,800 shares of common stock, respectively, at a weighted average price of $7.6209. The shares were sold in multiple transactions at prices ranging from $7.50 to $8.02. Following such sales, BC LS and BCIP LS held 3,658,228 and 374,454 shares of common stock, respectively.

F5: On December 19, 2017, BC LS and BCIP LS sold 50,101 and 5,128 shares of common stock, respectively, at a weighted average price of $7.1055. The shares were sold in multiple transactions at prices ranging from $6.86 to $7.498. Following such sales, BC LS and BCIP LS held 3,608,127 and 369,326 shares of common stock, respectively.

F6: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4.

F7: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS.

F8: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Replimune Group, Inc.

Report date July 24, 2018 · Filed July 26, 2018

Jointly reported with Bain Capital Life Sciences Investors, LLC, Bain Capital Life Sciences Partners, LP, Bain Capital Life Sciences Fund, L.P., BCIP Life Sciences Associates, LP, Koppel Adam

Section 16 reporting ended · disclosed 2018-07-26. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,338,968	Reported balance After 2018-07-24 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-07-24 · Conversion · Acquired 2,338,968 · Balance 2,338,968 F3: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date. F1: Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the "Bain Life Sciences Entities"). F2: The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee Footnotes	2,838,968	Reported balance After 2018-07-24 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-07-24 · Purchase · Acquired 500,000 · Balance 2,838,968 F4: On July 24, 2018, the Bain Life Sciences Entities purchased, in aggregate, 500,000 shares of Common Stock of the Issuer at a price of $15 per share, pursuant to an underwritten public offering. F1: Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the "Bain Life Sciences Entities"). F2: The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2018-07-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-07-24 · Conversion · Disposed 235,146 · Balance 0 F3: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date. F1: Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the "Bain Life Sciences Entities"). F2: The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares held directly by Bain Capital Life Sciences Fund, L.P. and BCIP Life Sciences Associates, LP (collectively, the "Bain Life Sciences Entities").

F2: The governance, investment strategy and decision-making process with respect to investments held by the Bain Life Sciences Entities is directed by Bain Capital Life Sciences Investors, LLC ("BCI LS"), whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

F3: Each share of Series B Convertible Preferred Stock automatically converted into shares of Common Stock on a 1-for-9.94688 basis upon the consummation of the Issuer's initial public offering without payment or additional consideration. The shares of Series B Convertible Preferred Stock had no expiration date.

F4: On July 24, 2018, the Bain Life Sciences Entities purchased, in aggregate, 500,000 shares of Common Stock of the Issuer at a price of $15 per share, pursuant to an underwritten public offering.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 18, 2017 Filed Dec 19, 2017 21:52 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Exercise / conversionRedeemable Convertible Preferred Stock · Derivative	250,000	$3.19	$797,500.00	Disclosure SEC source: 0000899243-17-029183 · doc4.xml · derivative · entry 4 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · Director · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · Director · 10% owner Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · Director · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · Director · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 0 Underlying: Common Stock · 8,454,388 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the "Stated Value") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power. F3 · derivative.exercise_price: On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively. F2 · derivative.exercise_date: Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the "Stated Value") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power. F3 · derivative.exercise_date: On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively. F2 · derivative.expiration_date: Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the "Stated Value") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power. F3 · derivative.expiration_date: On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F6 · ownership.nature: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:52 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	GrantCommon Stock	190,849	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-029183 · doc4.xml · nonDerivative · entry 3 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · Director · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · Director · 10% owner Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · Director · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · Director · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 8,930,237 F2 · price: Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the "Stated Value") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power. F4 · price: On December 18, 2017, each of BC LS and BCIP LS received an additional 172,633 and 18,216 shares of common stock, respectively, from the Issuer representing the additional dividend accruals on the Redeemable Convertible Preferred Stock that each of BC LS and BCIP LS would have been entitled to receive up to and including March 31, 2018. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F6 · ownership.nature: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:52 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	Exercise / conversionCommon Stock	8,454,388	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-17-029183 · doc4.xml · nonDerivative · entry 2 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · Director · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · Director · 10% owner Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · Director · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · Director · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 8,739,388 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: Each share of Redeemable Convertible Preferred Stock had a stated value of $100 (the "Stated Value") and accrued dividends daily at an initial rate of 12% per annum, which was reduced to 8% per annum on October 28, 2017 in accordance with the Certificate of Designations for the Redeemable Convertible Preferred Stock. The Stated Value, as adjusted to give effect to such dividends, was referred to as the "Accrued Value." Each share of Redeemable Convertible Preferred Stock was convertible, at the option of the holder or, upon the occurrence of certain events, at the option of the Issuer, into a number of shares of common stock determined by dividing the Accrued Value by the conversion price. The Redeemable Convertible Preferred Stock was not convertible to the extent that such conversion would have resulted in the beneficial owner of such Redeemable Convertible Preferred Stock and its affiliates owning in excess of 19.99% of the Issuer's voting power. F3 · price: On December 18, 2017, the 226,139 shares of Redeemable Convertible Preferred Stock held by BC LS and the 23,861 shares of Redeemable Convertible Preferred Stock held by BCIP LS were converted, at the option of the Bain Life Sciences Entities, into 7,647,468 and 806,920 shares of common stock, respectively. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F6 · ownership.nature: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
December 18, 2017 Filed Dec 19, 2017 21:52 UTC	Dicerna Pharmaceuticals Inc DRNA · Entity 131951	PurchaseCommon Stock	285,000	$7.00	$1,995,000.00	Disclosure SEC source: 0000899243-17-029183 · doc4.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · Director · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · Director · 10% owner Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · Director · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · Director · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · Director · 10% owner Koppel Adam · CIK 0001578965 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 285,000 F1 · kind: On December 18, 2017, Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Life Sciences Entities") purchased 257,798 and 27,202 shares of common stock, respectively, in an underwritten public offering. F5 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F6 · ownership.nature: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
December 18, 2017 Filed Dec 20, 2017 01:30 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	SaleCommon Stock	300,000	$7.50	$2,251,440.00	Disclosure SEC source: 0000899243-17-029256 · doc4.xml · nonDerivative · entry 3 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,127,453 F3 · shares: On December 18, 2017, BC LS and BCIP LS sold 272,143 and 27,857 shares of common stock, respectively, at a weighted average price of $7.5048. The shares were sold in multiple transactions at prices ranging from $7.05 to $7.905. Following such sales, BC LS and BCIP LS held 3,744,199 and 383,254 shares of common stock, respectively. F6 · shares: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F3 · price: On December 18, 2017, BC LS and BCIP LS sold 272,143 and 27,857 shares of common stock, respectively, at a weighted average price of $7.5048. The shares were sold in multiple transactions at prices ranging from $7.05 to $7.905. Following such sales, BC LS and BCIP LS held 3,744,199 and 383,254 shares of common stock, respectively. F6 · price: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8 · ownership.nature: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
December 15, 2017 Filed Dec 20, 2017 01:30 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	SaleCommon Stock	102,882	$8.64	$888,488.95	Disclosure SEC source: 0000899243-17-029256 · doc4.xml · nonDerivative · entry 2 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,427,453 F2 · shares: On December 15, 2017, BC LS and BCIP LS sold 93,329 and 9,553 shares of common stock, respectively, at a weighted average price of $8.636. The shares were sold in multiple transactions at prices ranging from $8.50 to $9.045. Following such sales, BC LS and BCIP LS held 4,016,342 and 411,111 shares of common stock, respectively. F6 · shares: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F2 · price: On December 15, 2017, BC LS and BCIP LS sold 93,329 and 9,553 shares of common stock, respectively, at a weighted average price of $8.636. The shares were sold in multiple transactions at prices ranging from $8.50 to $9.045. Following such sales, BC LS and BCIP LS held 4,016,342 and 411,111 shares of common stock, respectively. F6 · price: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8 · ownership.nature: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document
December 15, 2017 Filed Dec 20, 2017 01:30 UTC	MARINUS PHARMACEUTICALS, INC. MRNS · Entity 83359	SaleCommon Stock	719,665	$8.02	$5,770,202.00	Disclosure SEC source: 0000899243-17-029256 · doc4.xml · nonDerivative · entry 1 Bain Capital Life Sciences Investors, LLC · CIK 0001703031 · 10% owner Bain Capital Life Sciences Partners, LP · CIK 0001703030 · 10% owner Bain Capital Life Sciences Fund, L.P. · CIK 0001687968 · 10% owner BCIP Life Sciences Associates, LP · CIK 0001702921 · 10% owner Schwartz Jeffrey Lawrence · CIK 0001702957 · 10% owner Koppel Adam · CIK 0001578965 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 4,530,335 F1 · shares: On December 15, 2017, Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Life Sciences Entities") sold 652,840 and 66,825 shares of common stock, respectively, at a weighted average price of $8.0179. The shares were sold in multiple transactions at prices ranging from $7.89 to $8.495. Following such sales, BC LS and BCIP LS held 4,109,671 and 420,664 shares of common stock, respectively. F6 · shares: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F1 · price: On December 15, 2017, Bain Capital Life Sciences Fund, L.P. ("BC LS") and BCIP Life Sciences Associates, LP ("BCIP LS" and, together with BC LS, the "Bain Life Sciences Entities") sold 652,840 and 66,825 shares of common stock, respectively, at a weighted average price of $8.0179. The shares were sold in multiple transactions at prices ranging from $7.89 to $8.495. Following such sales, BC LS and BCIP LS held 4,109,671 and 420,664 shares of common stock, respectively. F6 · price: Each of the Bain Life Sciences Entities undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1) through (5) to this Form 4. F7 · ownership.nature: Bain Capital Life Sciences Investors, LLC ("BCI LS") is the general partner of Bain Capital Life Sciences Partners, LP ("BC LS P"), which is the general partner of BC LS. As a result, BC LS P may be deemed to share voting and dispositive power with respect to the securities held by BC LS. F8 · ownership.nature: The governance, investment strategy and decision-making process with respect to the investments held by the Bain Life Sciences Entities is directed by BCI LS, whose managers are Jeffrey Schwartz and Adam Koppel. As a result, BCI LS, Mr. Schwartz and Dr. Koppel may each be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. BCI LS, Mr. Schwartz and Dr. Koppel each disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.